IL293615A - Use of isatuzimab for the treatment of recurrent and/or resistant multiple myeloma - Google Patents

Use of isatuzimab for the treatment of recurrent and/or resistant multiple myeloma

Info

Publication number
IL293615A
IL293615A IL293615A IL29361522A IL293615A IL 293615 A IL293615 A IL 293615A IL 293615 A IL293615 A IL 293615A IL 29361522 A IL29361522 A IL 29361522A IL 293615 A IL293615 A IL 293615A
Authority
IL
Israel
Prior art keywords
antibody
individual
seq
amino acid
acid sequence
Prior art date
Application number
IL293615A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of IL293615A publication Critical patent/IL293615A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ceramic Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IL293615A 2019-12-06 2020-12-04 Use of isatuzimab for the treatment of recurrent and/or resistant multiple myeloma IL293615A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962944809P 2019-12-06 2019-12-06
EP20315186 2020-04-17
US202063023198P 2020-05-11 2020-05-11
US202063037353P 2020-06-10 2020-06-10
US202063094833P 2020-10-21 2020-10-21
PCT/US2020/063468 WO2021113754A1 (en) 2019-12-06 2020-12-04 Use of isatuximab for the treatment of relapsed and/or refractory multiple myeloma

Publications (1)

Publication Number Publication Date
IL293615A true IL293615A (en) 2022-08-01

Family

ID=74046182

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293615A IL293615A (en) 2019-12-06 2020-12-04 Use of isatuzimab for the treatment of recurrent and/or resistant multiple myeloma

Country Status (13)

Country Link
US (1) US20210171653A1 (cg-RX-API-DMAC10.html)
EP (1) EP4069740A1 (cg-RX-API-DMAC10.html)
JP (2) JP7704751B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220159948A (cg-RX-API-DMAC10.html)
CN (1) CN115698065A (cg-RX-API-DMAC10.html)
AU (1) AU2020398655A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022010907A2 (cg-RX-API-DMAC10.html)
CA (1) CA3164026A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022009433A2 (cg-RX-API-DMAC10.html)
IL (1) IL293615A (cg-RX-API-DMAC10.html)
MX (1) MX2022006883A (cg-RX-API-DMAC10.html)
TW (2) TWI887310B (cg-RX-API-DMAC10.html)
WO (1) WO2021113754A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4536278A4 (en) 2022-06-07 2026-08-12 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
SG10201913777XA (en) * 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
MX373301B (es) * 2013-10-31 2020-04-24 Sanofi Sa Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
US11618787B2 (en) * 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma

Also Published As

Publication number Publication date
MX2022006883A (es) 2022-11-08
JP7704751B2 (ja) 2025-07-08
JP2025138745A (ja) 2025-09-25
WO2021113754A1 (en) 2021-06-10
TWI887310B (zh) 2025-06-21
TW202610683A (zh) 2026-03-16
BR112022010907A2 (pt) 2022-10-18
CO2022009433A2 (es) 2022-07-29
JP2023505219A (ja) 2023-02-08
AU2020398655A1 (en) 2022-07-28
TWI922320B (zh) 2026-04-11
EP4069740A1 (en) 2022-10-12
US20210171653A1 (en) 2021-06-10
CN115698065A (zh) 2023-02-03
TW202133880A (zh) 2021-09-16
KR20220159948A (ko) 2022-12-05
CA3164026A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
JP7712206B2 (ja) 多発性骨髄腫の処置方法
JP7801132B2 (ja) 抗cd38抗体を投与して多発性骨髄腫を処置する方法
IL251464B (en) Combination therapy for cancer
US20240025978A1 (en) Methods for treating complement-mediated diseases
JP2025138745A (ja) 再発性および/または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用
TW202541838A (zh) 抗cd38抗體在治療新診斷的多發性骨髓瘤中之用途
RU2858309C2 (ru) Применение изатуксимаба для лечения рецидивирующей и/или рефрактерной множественной миеломы
JP2025503176A (ja) びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体
CA3048198A1 (en) Methods of treating multiple myeloma
IL295202A (en) Anti-cd30 antibody-drug conjugates and their use for the treatment of non-Hodgkin's lymphoma
RU2838203C2 (ru) Способы лечения множественной миеломы
TWI886758B (zh) 抗pvrig/抗tigit雙特異性抗體在治療惡性腫瘤中的用途
US20260116977A1 (en) Methods of treating melanoma using an anti-ctla4 antibody
IL303350A (en) Preparations containing an antibody against HER2/NEU and their use
WO2025094087A1 (en) Safe administration of a2a rector antagonist
EA053286B1 (ru) Способ лечения амилоидоза
WO2026104504A1 (en) Dosing of prame-specific tcer